Colorectal carcinoma (CRC) · line 1 · FOLFOX + Bevacizumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-FOLFOX-BEV`

ID	`IND-CRC-METASTATIC-1L-FOLFOX-BEV`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

RAS-mutant OR right-sided RAS-WT — anti-VEGF track.

Used By

Algorithms

ALGO-CRC-METASTATIC-1L - ALGO-CRC-METASTATIC-1L

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning